Israël - Engels - Ministry of Health

teva pharmaceutical industries ltd, israel - formoterol fumarate - powder for inhalation - formoterol fumarate 9 mcg/dose - formoterol - formoterol - for the relief of broncho-obstructive symptoms and prevention of exercise-induced symptoms in asthmatics when adequate treatment with corticosteroids is not sufficient for the relief of bronco-obstructive symptoms in patients with chronic obstructive pulmonary disease (copd).

Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - formoterol fumarate; budesonide bp -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - formoterol fumarate dihydrate, quantity: 0.8 mg; fluticasone propionate, quantity: 8 mg - inhalation, pressurised - excipient ingredients: ethanol absolute; sodium cromoglycate; apaflurane - flutiform inhaler is indicated for the regular maintenance treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2-agonist) is appropriate. this includes patients not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonist on an ?as required? basis.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - bevespi aerosphere is indicated as a long-term twice-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (copd).

Europese Unie - Engels - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - brimica genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Kenia - Engels - Pharmacy and Poisons Board

bliss gvs pharma limited 102, hyde park, saki vihar road, andheri (east) - - formoterol fumarate and budesonide inhalation - pressurised inhalation - each actuation delivers: formoterol fumarate… - formoterol and budesonide

Kenia - Engels - Pharmacy and Poisons Board

bliss gvs pharma ltd 102, hyde park, saki-vihar road, andheri (east), - formoterol fumarate and budesonide inhalation - pressurised inhalation - each actuation delivers: formoterol fumarate… - formoterol and budesonide

Ierland - Engels - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - formoterol fumatrate dihydrate - powder for inhalation - 6 microgram(s) - selective beta-2-adrenoreceptor agonists; formoterol

Europese Unie - Engels - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Europese Unie - Engels - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).